GICS Sector : Healthcare
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.Taysha Gene Therapies, Inc.
Taysha Gene Therapies reported a net loss of $32.7 million for the third quarter of 2025, compared to a net loss of $25.5 million for the same period in 2024. Research and development expenses were $25.7 million, up from $14.9 million in the third quarter of 2024. The company's cash and cash equivalents stood at $297.3 million as of September 30, 2025, expected to support planned operating expenses and capital requirements into 2028. The actual EPS came in at -$0.09, in line with estimates. The company's financial performance is characterized by significant R&D expenses, which is typical for a biotech firm in the development stage.
Publication Date: Nov -26
Taysha made significant progress in its TSHA-102 Rett syndrome program, including FDA Breakthrough Therapy designation, alignment with the FDA on the REVEAL pivotal trial protocol, and statistical analysis plan. The company is enrolling 15 patients in the developmental plateau population of Rett syndrome, with a primary endpoint of response rate. According to Sean Nolan, "with Breakthrough Therapy designation and finalized FDA alignment, Taysha is entering the pivotal phase of development with focus and confidence in its ability to redefine the treatment landscape for Rett syndrome while driving long-term value."
The company's valuation metrics indicate a high level of investment in its growth prospects. The P/S Ratio stands at 165.75, and the EV/EBITDA is -7.63, reflecting the market's expectations for future growth. Analysts estimate next year's revenue growth at -30.0%, indicating a decline in revenue. The ROE and ROIC are also negative, at -67.26% and -35.47%, respectively, highlighting the company's current unprofitability.
Taysha plans to accelerate patient enrollment in the pivotal trial by staggering parallel sites, potentially shortening the submission timeline for the Biologics License Application (BLA). The company expects to provide updates on long-term data in the first half of next year, focusing on the full cohort of 12 patients at 12 months and the safety profile. The enrollment for the pivotal trial is expected to begin in the middle of 2026.
Sukumar Nagendran Sells 260,047 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock
Dec -03
Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript
Nov -04
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov -04
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
Oct -28
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.1% – Time to Buy?
Oct -22
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Moderate Buy” by Analysts
Oct -22
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Oct -16
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Oct -09
Growing demand for gene therapies, increasing prevalence of genetic diseases, and advancements in AAV vector technology are driving the growth of Adeno-Associated Viruses-based Gene Therapies market.
Gene therapy for the treatment of Giant Axonal Neuropathy (GAN), a rare and debilitating genetic disorder that affects the nerve cells.
Gene therapy for the treatment of Charcot-Marie-Tooth disease (CMT), a group of inherited disorders that affect the peripheral nerves.
Gene therapy for the treatment of Rett syndrome, a rare genetic disorder that affects brain development and function.
Gene therapy for the treatment of Friedreich's ataxia, a rare inherited disorder that affects the nervous system and causes progressive damage to the cerebellum.
Taysha Gene Therapies, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to ongoing research and development in the gene therapy space.
Taysha Gene Therapies, Inc. has a diverse customer base, and no single customer has significant bargaining power, reducing the threat of customer bargaining power.
Taysha Gene Therapies, Inc. relies on a few key suppliers for raw materials and equipment, giving them some bargaining power, but the company's strong relationships and diversification efforts mitigate this threat.
The gene therapy market is rapidly growing, and new entrants are attracted to the market, increasing the threat of new entrants and competition for Taysha Gene Therapies, Inc.
The gene therapy market is highly competitive, with several established players and new entrants, leading to a high intensity of rivalry for Taysha Gene Therapies, Inc.
| Value | |
|---|---|
| Debt Weight | 36.00% |
| Debt Cost | 5.67% |
| Equity Weight | 64.00% |
| Equity Cost | 5.67% |
| WACC | 5.67% |
| Leverage | 56.25% |
Value: 7.6
Growth: 6.4
Quality: 6.8
Yield: 0.0
Momentum: 5.0
Volatility: 1.7
1-Year Total Return ->
Value: 1.2
Growth: 8.4
Quality: 6.4
Yield: 0.0
Momentum: 6.0
Volatility: 3.7
1-Year Total Return ->
Value: 6.2
Growth: 4.9
Quality: 4.2
Yield: 0.0
Momentum: 9.0
Volatility: 0.7
1-Year Total Return ->
Value: 9.0
Growth: 3.7
Quality: 6.0
Yield: 0.0
Momentum: 0.5
Volatility: 1.0
1-Year Total Return ->
Value: 7.8
Growth: 3.7
Quality: 3.7
Yield: 0.0
Momentum: 1.0
Volatility: 0.7
1-Year Total Return ->
Value: 6.8
Growth: 3.9
Quality: 3.4
Yield: 0.0
Momentum: 2.0
Volatility: 0.7
1-Year Total Return ->